CoChat
Sign Up
Cited by 10Dermatology and Skin DiseasesContact Dermatitis and AllergiesPsoriasis: Treatment and Pathogenesis

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Topical proactive therapy in dermatology. A scoping review

Open access
Makowska, Karolina, Nowaczyk, Joanna, Samochocki, Zbigniew, Blicharz, Leszek, Rudnicka, Lidia·2023·Advances in Dermatology and Allergology
DOI 10.5114/ada.2023.129454PMC PMC10485751
Open this paper in CoChat — free accountOpen PDF

Abstract

The term 'proactive therapy' refers to a long-term management of clinically intact skin in previously disease-affected areas. This method was initially implemented in atopic dermatitis to maintain the remission and decrease the risk of exacerbations. Proactive therapy aims to limit the need for reactive treatment and improve the patients' quality of life. A proactive approach is likely to be adopted for other relapsing and inflammatory skin conditions in the future. This scoping review aims to identify dermatological conditions to be treated with the proactive approach, evaluate the available evidence for its efficacy and safety, as well as highlight the research gaps.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.5114/ada.2023.129454

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 64

  1. [1]Wollenberg A, Frank R, Kroth J, Ruzicka T. Proactive therapy of atopic eczema--an evidence-based concept with a behavioral background. J Dtsch Dermatol Ges 2009; 7: 117- 21. 18691346
  2. [2]Wollenberg A, Reitamo S, Girolomoni G, et al. Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. Allergy 2008; 63: 742- 50. 18592619
  3. [3]Van Der Meer JB, Glazenburg EJ, Mulder PG, et al. The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate. The Netherlands Adult Atopic Dermatitis Study Group. Br J Dermatol 1999; 140: 1114- 21. 10354080
  4. [4]Hanifin J, Gupta AK, Rajagopalan R. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. Br J Dermatol 2002; 147: 528- 37. 12207596
  5. [5]Berth-Jones J, Damstra RJ, Golsch S, et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. BMJ 2003; 326: 1367. 12816824 PMC162129
  6. [6]Papp KA, Dhadwal G, Gooderham M, et al. Emerging paradigm shift toward proactive topical treatment of psoriasis: a narrative review. Dermatol Ther 2021; 34: e15104. 34418251 PMC9286633
  7. [7]Wollenberg A, Bieber T. Proactive therapy of atopic dermatitis – an emerging concept. Allergy 2009; 64: 276- 78. 19076538
  8. [8]Benezeder T, Wolf P. Resolution of plaque-type psoriasis: what is left behind (and reinitiates the disease). Semin Immunopathol 2019; 41: 633- 44. 31673756 PMC6881414
  9. [9]Lebwohl M, Thaçi D, Warren RB. Addressing challenges associated with long-term topical treatment and benefits of proactive management in patients with psoriasis. J Eur Acad Dermatol Venereol 2021; 35 Suppl 1: 35- 41. 33619776 PMC7985873
  10. [10]Mueller SM, Itin P, Vogt DR, et al. Assessment of “corticophobia” as an indicator of non-adherence to topical corticosteroids: a pilot study. J Dermatol Treat 2017; 28: 104- 11. 27396480
  11. [15]Wollenberg A, Christen-Zäch S, Taieb A, et al. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol 2020; 34: 2717- 44. 33205485
  12. [16]Barbarot S, Silverberg JI, Gadkari A, et al. The family impact of atopic dermatitis in the pediatric population: results from an international cross-sectional study. J Pediatr 2022; 246: 220- 6.e5. 35490745
  13. [17]Egeberg A, Anderson P, Piercy J, et al. Symptom burden of patients with moderate-to-severe atopic dermatitis. Eur J Dermatol 2021; 31: 752- 8. 34935621
  14. [18]Glazenburg EJ, Wolkerstorfer A, Gerretsen AL, et al. Efficacy and safety of fluticasone propionate 0.005% ointment in the long-term maintenance treatment of children with atopic dermatitis: differences between boys and girls? Pediatr Allergy Immunol 2009; 20: 59- 66. 18298423
  15. [19]Paller AS, Eichenfield LF, Kirsner RS, et al. Three times weekly tacrolimus ointment reduces relapse in stabilized atopic dermatitis: a new paradigm for use. Pediatrics 2008; 122: e1210- 8. 19015204
  16. [20]Breneman D, Fleischer AB, Abramovits W, et al. Intermittent therapy for flare prevention and long-term disease control in stabilized atopic dermatitis: a randomized comparison of 3-times-weekly applications of tacrolimus ointment versus vehicle. J Am Acad Dermatol 2008; 58: 990- 9. 18359127
  17. [21]Thaçi D, Reitamo S, Gonzalez Ensenat MA, et al. Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study. Br J Dermatol 2008; 159: 1348- 56. 18782319
  18. [22]Peserico A, Städtler G, Sebastian M, et al. Reduction of relapses of atopic dermatitis with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient: a multicentre, randomized, double-blind, controlled study. Br J Dermatol 2008; 158: 801- 7. 18284403
  19. [23]Lax SJ, Harvey J, Axon E, et al. Strategies for using topical corticosteroids in children and adults with eczema. Cochrane Database Syst Rev 2022; 2022: CD013356. PMC8916090 35275399
  20. [24]Kamiya K, Saeki H, Tokura Y, et al. Proactive versus rank-down topical corticosteroid therapy for maintenance of remission in pediatric atopic dermatitis: a randomized, open-label, active-controlled, parallel-group study (anticipate study). J Clin Med 2022; 11: 6477. 36362704 PMC9658234
  21. [25]Danby SG, Chittock J, Brown K, et al. The effect of tacrolimus compared with betamethasone valerate on the skin barrier in volunteers with quiescent atopic dermatitis. Br J Dermatol 2014; 170: 914- 21. 24328907
  22. [26]Chittock J, Brown K, Cork MJ, Danby SG. Comparing the effect of a twice-weekly tacrolimus and betamethasone valerate dose on the subclinical epidermal barrier defect in atopic dermatitis. Acta Derm Venereol 2015; 95: 653- 8. 25594610
  23. [27]Aschoff R, Schmitt J, Knuschke P, et al. Evaluation of the atrophogenic potential of hydrocortisone 1% cream and pimecrolimus 1% cream in uninvolved forehead skin of patients with atopic dermatitis using optical coherence tomography. Exp Dermatol 2011; 20: 832- 6. 21771098
  24. [28]Aschoff R, Lang A, Koch E. Effects of intermittent treatment with topical corticosteroids and calcineurin inhibitors on epidermal and dermal thickness using optical coherence tomography and ultrasound. Skin Pharmacol Physiol 2022; 35: 41- 50. 34348352 PMC8820417
  25. [29]Suehiro M, Numata T, Murakami E, et al. Real-world efficacy of proactive maintenance treatment with delgocitinib ointment twice weekly in adult patients with atopic dermatitis. Dermatol Ther 2022; 35: e15526. 35441769
  26. [30]Boehncke WH, Schön MP. Psoriasis. Lancet 2015; 386: 983- 94. 26025581
  27. [31]Segaert S, Calzavara-Pinton P, de la Cueva P, et al. Long-term topical management of psoriasis: the road ahead. J Dermatol Treat 2022: 33: 111- 20. 32091278
  28. [32]Jalili A, Calzavara-Pinton P, Kircik L, et al. Quality of life and patient-perceived symptoms in patients with psoriasis undergoing proactive or reactive management with the fixed-dose combination Cal/BD foam: a post-hoc analysis of PSO-LONG. J Eur Acad Dermatol Venereol 2022; 36: 60- 7. 34543474 PMC9298373
  29. [33]Mahé E. Optimal management of plaque psoriasis in adolescents: current perspectives. Psoriasis Auckl NZ 2020; 10: 45- 56. PMC7708777 33274179
  30. [34]Augustin M, Mrowietz U, Bonnekoh B, et al. Topical long-term therapy of psoriasis with vitamin D₃ analogues, corticosteroids and their two compound formulations: position paper on evidence and use in daily practice. J Dtsch Dermatol Ges 2014; 12: 667- 82. 25039309
  31. [35]Katz HI, Prawer SE, Medansky RS, et al. Intermittent corticosteroid maintenance treatment of psoriasis: a double-blind multicenter trial of augmented betamethasone dipropionate ointment in a pulse dose treatment regimen. Dermatologica 1991; 183: 269- 74. 1809589
  32. [36]Lebwohl M, Kircik L, Lacour JP, et al. Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial). J Am Acad Dermatol 2021; 84: 1269- 77. 32950546
  33. [37]Stein-Gold L, Alonso-Llamazares J, Lacour J, et al. PSO-LONG: Design of a novel, 12-month clinical trial of topical, proactive maintenance with twice-weekly Cal/BD foam in psoriasis. Adv Ther 2020; 37: 4730- 53. 32965655 PMC7547957
  34. [38]Papp K, Adamski Z, Guenther L, et al. Proactive treatment of plaque psoriasis with twice-a-week application of Cal/BD spray foam is safe in patients who underwent a functional test of the HPA axis. J Dtsch Dermatol Ges 2021; 19: 69- 70.
  35. [39]De Simone C, Dapavo P, Malagoli P, et al. Long-term proactive management of psoriasis with calcipotriol and betamethasone dipropionate foam: an Italian consensus through a combined nominal group technique and Delphi approach. Int J Dermatol 2022; 61: 1543- 51. 35609147 PMC9790732
  36. [40]Cacciapuoti S, Ruggiero A, Gallo L, Fabbrocini G. Proactive vs. reactive psoriasis therapy: a long-term evaluation with dermoscopic and confocal microscopy assessment. Eur Rev Med Pharmacol Sci 2022; 26: 2018- 24. 35363352
  37. [41]Maul JT, Anzengruber F, Conrad C, et al. Topical treatment of psoriasis vulgaris: the Swiss treatment pathway. Dermatology 2021; 237: 166- 78. 33406520
  38. [42]Adam DN, Jablonski Bernasconi MY, Thoning H, Wu JJ. Matching-adjusted indirect comparison of long-term efficacy and safety outcomes for calcipotriol plus betamethasone dipropionate foam versus halobetasol proprionate plus tazarotene lotion in the treatment of plaque psoriasis. Dermatol Ther 2022; 12: 2589- 600. PMC9588120 36223060
  39. [43]Paul C, Stein Gold L, Cambazard F, et al. Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO-ABLE study. J Eur Acad Dermatol Venereol 2017; 31: 119- 26. 27531752 PMC6207928
  40. [44]Griffiths CE, Stein Gold L, Cambazard F, et al. Greater improvement in quality of life outcomes in patients using fixed-combination calcipotriol plus betamethasone dipropionate aerosol foam versus gel: results from the PSO-ABLE study. Eur J Dermatol 2018; 28: 356- 63. 29952297
  41. [45]Rudnicka L, Olszewska M, Goldust M, et al. Efficacy and safety of different formulations of calcipotriol/betamethasone dipropionate in psoriasis: gel, foam, and ointment. J Clin Med 2021; 10: 5589. 34884291 PMC8658256
  42. [46]Hong CH, Papp KA, Lophaven KW, et al. Patients with psoriasis have different preferences for topical therapy, highlighting the importance of individualized treatment approaches: randomized phase IIIb PSO-INSIGHTFUL study. J Eur Acad Dermatol Venereol 2017; 31: 1876- 83. 28796913 PMC5698702
  43. [47]Gupta AK, Versteeg SG. Topical treatment of facial seborrheic dermatitis: a systematic review. Am J Clin Dermatol 2017; 18: 193- 213. 27804089
  44. [48]Kim TW, Mun JH, Jwa SW, et al. Proactive treatment of adult facial seborrhoeic dermatitis with 0.1% tacrolimus ointment: randomized, double-blind, vehicle-controlled, multi-centre trial. Acta Derm Venereol 2013; 93: 557- 61. 23388687
  45. [49]Joly P, Tejedor I, Tetart F, et al. Tacrolimus 0.1% versus ciclopiroxolamine 1% for maintenance therapy in patients with severe facial seborrheic dermatitis: a multicenter, double-blind, randomized controlled study. J Am Acad Dermatol 2021; 84: 1278- 84. 33010323
  46. [50]Kirtschig G. Lichen sclerosus – presentation, diagnosis and management. Dtsch Ärztebl Int 2016; 113: 337- 43. 27232363 PMC4904529
  47. [51]Chin S, Scurry J, Bradford J, et al. Association of topical corticosteroids with reduced vulvar squamous cell carcinoma recurrence in patients with vulvar lichen sclerosus. JAMA Dermatol 2020; 156: 813- 4. 32374363 PMC7203667
  48. [52]Lewis FM, Tatnall FM, Velangi SS, et al. British Association of Dermatologists guidelines for the management of lichen sclerosus, 2018. Br J Dermatol 2018; 178: 839- 53. 29313888
  49. [53]Wijaya M, Lee G, Fischer G, Lee A. Quality of life in vulvar lichen sclerosus patients treated with long-term topical corticosteroids. J Low Genit Tract Dis 2021; 25: 158- 65. 33746196
  50. [54]Kravvas G, Shim TN, Doiron PR, et al. The diagnosis and management of male genital lichen sclerosus: a retrospective review of 301 patients. J Eur Acad Dermatol Venereol 2018; 32: 91- 5. 28750140
  51. [55]Virgili A, Minghetti S, Borghi A, Corazza M. Proactive maintenance therapy with a topical corticosteroid for vulvar lichen sclerosus: preliminary results of a randomized study. Br J Dermatol 2013; 168: 1316- 24. 23398459
  52. [56]Corazza M, Borghi A, Minghetti S, et al. Clobetasol propionate vs. mometasone furoate in 1-year proactive maintenance therapy of vulvar lichen sclerosus: results from a comparative trial. J Eur Acad Dermatol Venereol 2016; 30: 956- 61. 25904498
  53. [57]Li Y, Xiao Y, Wang H, et al. Low-concentration topical tacrolimus for the treatment of anogenital lichen sclerosus in childhood: maintenance treatment to reduce recurrence. J Pediatr Adolesc Gynecol 2013; 26: 239- 42. 24049806
  54. [58]Kirtschig G, Becker K, Günthert A, et al. Evidence-based (S3) Guideline on (anogenital) lichen sclerosus. J Eur Acad Dermatol Venereol 2015; 29: e1- 43. 26202852
  55. [59]Patel H, Wagner M, Singhal P, Kothari S. Systematic review of the incidence and prevalence of genital warts. BMC Infect Dis 2013; 13: 39. 23347441 PMC3618302
  56. [60]O’Mahony C, Gomberg M, Skerlev M, et al. Position statement for the diagnosis and management of anogenital warts. J Eur Acad Dermatol Venereol 2019; 33: 1006- 19. 30968980 PMC6593709
  57. [62]Schöfer H, Tatti S, Lynde CW, et al. Sinecatechins and imiquimod as proactive sequential therapy of external genital and perianal warts in adults. Int J STD AIDS 2017; 28: 1433- 43. 28566057
  58. [63]Bertolotti A, Ferdynus C, Milpied B, et al. Local management of anogenital warts in non-immunocompromised adults: a network meta-analysis of randomized controlled trials. Dermatol Ther 2020; 10: 249- 62. PMC7090115 32030564
  59. [64]Schöfer H, Van Ophoven A, Henke U, et al. Randomized, comparative trial on the sustained efficacy of topical imiquimod 5% cream versus conventional ablative methods in external anogenital warts. Eur J Dermatol 2006; 16: 642- 8. 17229604
  60. [65]Carpiniello VL, Malloy TR, Sedlacek TV, Zderic SA. Results of carbon dioxide laser therapy and topical 5-fluorouracil treatment for subclinical condyloma found by magnified penile surface scanning. J Urol 1988; 140: 53- 4. 3379696
  61. [66]On SCJ, Linkner RV, Haddican M, et al. A single-blinded randomized controlled study to assess the efficacy of twice daily application of sinecatechins 15% ointment when used sequentially with cryotherapy in the treatment of external genital warts. J Drugs Dermatol 2014; 13: 1400- 5. 25607709
  62. [67]Feng C, Li W, Wang X, et al. A systematic review evaluating the efficacy and safety of a combination of ablative treatment and self administered treatment versus ablative treatment alone for external anogenital warts. Int J Dermatol 2020; 59: 1210- 6. 32297994
  63. [68]Juhl ME, Seferovic V, Antonijevic S, Krunic A. Combined treatment of anogenital HPV infection with cryodestruction, podophyllin 25% and post-ablation immunomodulation with sinecatechins 15% ointment – a retrospective analysis. Int J STD AIDS 2016; 27: 1071- 8. 26404110
  64. [69]Gilson R, Nugent D, Werner RN, et al. 2019 IUSTI-Europe guideline for the management of anogenital warts. J Eur Acad Dermatol Venereol 2020; 34: 1644- 53. 32735077

Cited by

Metadata

Authors
Makowska, K., Nowaczyk, J., Samochocki, Z., Blicharz, L., & Rudnicka, L.
Affiliations
Medical University of Warsaw (PL)
Corresponding author
Blicharz, Leszek
ORCID
Venue
Advances in Dermatology and Allergology
Publisher
Termedia Sp. z.o.o.
Published
2023
Volume
40
Issue
4
Pages
510-517
ISSN
  • 0860-6218 (ISSN-L)
  • 1642-395X
DOI
10.5114/ada.2023.129454
PMC
PMC10485751
OpenAlex
W4386381999
Cited by
10
References
4
Citations by year
2026: 3 · 2025: 2 · 2024: 5
FWCI
0.46
Type
journal article
Language
en
Open access
Locations
  • Advances in Dermatology and Allergology (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
  • Health Sciences › Medicine › Dermatology › Contact Dermatitis and Allergies
  • Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
Keywords
proactive therapy, topical treatment, atopic dermatitis, inflammatory skin diseases, remission, quality of life, treatment efficacy and safety

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review